NM-2201, also known as CBL-2201, is formally named naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, and its molecular formula is C24H22FNO2. It is one of many indole-based artificial cannabinoids. It has a λmax of 220, 294 nm, and a stability rating of one year. NM-2201
NM2201 is considered an alogue of AM2201, which is itself an artificial cannabinoid with Ki values of 1.0 for the CB1 receptor and 2.6 nM for the peripheral CB2 receptors. NM-2201’s full physiological effects have not been defined. It is suspected to have many similar effects to the closely related chemicals NNE1 and 5F-PB-22, each of which bind unselectively to both CB1 and CB2 receptors as full agonists with a similar nanomolar affinity.
AM-2201, formally 1-(5-fluoropentyl)-3-(1-naphthoyl)indole, is known as a powerful and nonselective agonist for human cannabinoid receptors. It is one of the AM line of cannabinoids which Alexandros Makriyannis discovered in the course of his work at Northeastern University.
AM-2201 and its an alogues are often used as an artificial cannabis substitute, and are considered to be the most potent of this class of chemicals. An ‘active dose’ is considered to be as little as 500 µg. Because the correct dosage is so small when used in this way, there is elevated risk of unintentional overdose, which should be considered in a forensics context.
There are several anecdotal accounts of panic or anxiety attacks associated with NM-2201or AM-2201 ingestion, and nausea is often reported in doses as low as 2 milligrams. Convulsion has been documented in doses of 10mg or greater.
NM-2201 is currently banned in Sweden, but in no other countries. As of May 2015, Germany was considering scheduling NM-2201 as an Anlage I controlled substance.